Stockscreener 앱 받기
10.26
9.38%
0.88
시간 외 거래:
10.00
-0.26
-2.53%
전일 마감가:
$9.38
열려 있는:
$9.5
하루 거래량:
9.25M
Relative Volume:
2.57
시가총액:
$651.52M
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-4.4609
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
+21.71%
1개월 성능:
-81.07%
6개월 성능:
-69.80%
1년 성능:
-78.17%
1일 변동 폭
$9.34
$10.59
1주일 범위
$8.1773
$10.59
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
MLTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
10.26 | 595.64M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics - TipRanks
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & - GlobeNewswire
Insider Stock Purchases: October 09, 2025 - Quiver Quantitative
MoonLake Immunotherapeutics Stock (MLTX) Opinions on Phase 3 Trial Setback - Quiver Quantitative
Insider Buying: Matthias Bodenstedt Acquires Shares of MoonLake Immunotherapeutics - GuruFocus
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock - Investing.com
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock By Investing.com - Investing.com UK
BFA Law is Investigating MoonLake Immunotherapeutics (MLTX) for Securities Fraud and Urges Shareholders to Contact the Firm - Newsfile
Measuring MoonLake Immunotherapeutics’s beta against major indicesFed Meeting & Daily Growth Stock Tips - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake ImmunotherapeuticsMLTX - PR Newswire
MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with - GlobeNewswire
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
MLTX ALERT: Levi & Korsinsky Investigates MoonLake Immunotherapeutics on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Oppenheimer lowers Moonlake Immunotherapeutics stock price target after mixed trial results - Investing.com
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics - GlobeNewswire
MoonLake Immunotherapeutics Investors Should Contact Block - GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake - GlobeNewswire
MLTX ACTIVE INVESTIGATION: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky Now - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud by MoonLake Immunotherapeutics (MLTX) - ACCESS Newswire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
MoonLake Immunotherapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny - GlobeNewswire
What is HC Wainwright’s Forecast for MLTX FY2025 Earnings? - Defense World
MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Investors to Reach Out - ACCESS Newswire
MoonLake Immunotherapeutics (MLTX): Valuation in Focus After VELA HS Trial Setback and Market Scrutiny - simplywall.st
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Benzinga
Leading vs lagging indicators on MoonLake Immunotherapeutics performance2025 Fundamental Recap & Technical Buy Zone Confirmation - newser.com
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on - The National Law Review
Ongoing MoonLake Immunotherapeutics (MLTX) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Combining price and volume data for MoonLake ImmunotherapeuticsRisk Management & Daily Profit Focused Screening - newser.com
What earnings revisions data tells us about MoonLake ImmunotherapeuticsSwing Trade & AI Driven Stock Price Forecasts - newser.com
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
MoonLake Immunotherapeutics results for Phase 3 VELA-1, VELA-2 trials - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Stockholders to Reach Out - ACCESS Newswire
ATTENTION MLTX Shareholders: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Did MoonLake Immunotherapeutics (MLTX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
The week in pharma: action, reaction and insight – week to October 3 - The Pharma Letter
Is MoonLake Immunotherapeutics stock a buy before product launchesJuly 2025 Opening Moves & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-05 03:26:36 - newser.com
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results - MSN
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces - GlobeNewswire
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $16 - 富途牛牛
MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny - Yahoo Finance
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
MLTX Investor ALERT: Block & Leviton Investigating MoonLake Immunotherapeutics For Securities Fraud; Investors Should Contact The Firm To Potentially Recover Losses - ACCESS Newswire
Why MoonLake Immunotherapeutics (MLTX) Is Down 86.8% After Sonelokimab Phase 3 Trial Misses Key Goal - simplywall.st
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
| Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
5.74%
자본화:
|
볼륨(24시간):